News Release

Posted date:

ARTham Therapeutics Presents Phase I Results for both ART-001 and ART-648 at ASCPT 2021 Annual Meeting

YOKOHAMA, January 15, 2021 – ARTham Therapeutics, Inc. will present Phase I results for both ART-648, an investigational PDE4 inhibitor, and ART-001, an investigational PI3Kα inhibitor in a poster session at the American Society for Clinical Pharmacology and Therapeutics (ASCPT) 2021 Annual Meeting (March 8-17, 2021). ART-648 is an orally-available, selective and potent inhibitor of PDE4 in development for the treatment of bullous pemphigoid and COVID-19. ART-001 is an orally-available selective PI3Kα inhibitor in development for the treatment of slow-flow vascular malformations. Details of the poster presentations are as follows:

Abstract title: PII-040 – The novel PDE4 inhibitor ART-648 exhibits robust target engagement at clinically safe and tolerated doses identified in healthy subjects

Abstract title: PII-041 – Safety and pharmacokinetics of novel PI3Kα inhibitor ART-001 in oral pediatric formulation for the treatment of vascular malformations

Session title: Interactive Poster Hour II

Date & Time: Friday, March 12, 6:00 – 7:00 pm (EST)


About ART-648

ART-648 is an orally-available PDE4 inhibitor that is currently under development for bullous pemphigoid and COVID-19. ART-648 potently and selectively inhibits PDE4 enzyme and exhibits direct “anti-inflammatory,” “antimetabolite,” and “antifibrotic” effects in multiple disease relevant in vitro or in vivo models. In addition, ART-648 possesses superior physico-chemical properties, which contribute to tolerability profile similar or better to marketed PDE4 inhibitors. Phase IIa trials are scheduled to initiate in late 2021.


About ART-001

ART-001 is an orally-available PI3Kα inhibitor that is currently under development for low-flow vascular malformations. ART-001 potently and selectively inhibited PI3Kα and exhibits “antitumor effect” and “anti-angiogenesis effect” in in vitro and in vivo preclinical models. In addition, the excellent pharmacokinetic and safety profile with the new formulation was demonstrated in the Phase I study in healthy adults. The new formulation will also enable administration in pediatric patients. Phase IIa trials are scheduled to initiate in late 2021.


About ARTham Therapeutics

ARTham Therapeutics is a clinical stage biopharmaceutical company that will deliver “medicines that matter” for patients, with a compelling portfolio developed through unraveling hidden value of existing pharma assets. ARTham is a virtual R&D company that seeks the best academic and business partners to rapidly develop high value clinical candidates. The company is headquartered in Yokohama, Japan. For more information, please visit



Tel: +81-45-225-8858